JP2005505557A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005505557A5 JP2005505557A5 JP2003526372A JP2003526372A JP2005505557A5 JP 2005505557 A5 JP2005505557 A5 JP 2005505557A5 JP 2003526372 A JP2003526372 A JP 2003526372A JP 2003526372 A JP2003526372 A JP 2003526372A JP 2005505557 A5 JP2005505557 A5 JP 2005505557A5
- Authority
- JP
- Japan
- Prior art keywords
- agents
- agent
- medicine
- pharmaceutically active
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 3
- -1 biologicals Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 206010000410 Acetonaemia Diseases 0.000 claims 1
- 102000018997 Growth Hormone Human genes 0.000 claims 1
- 108010051696 Growth Hormone Proteins 0.000 claims 1
- 208000007976 Ketosis Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 239000002535 acidifier Substances 0.000 claims 1
- 229940095602 acidifiers Drugs 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 229940124325 anabolic agent Drugs 0.000 claims 1
- 239000003263 anabolic agent Substances 0.000 claims 1
- 230000003444 anaesthetic effect Effects 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 230000001458 anti-acid effect Effects 0.000 claims 1
- 230000001773 anti-convulsant effect Effects 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 230000002924 anti-infective effect Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 230000000840 anti-viral effect Effects 0.000 claims 1
- 229940124346 antiarthritic agent Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 229960003965 antiepileptics Drugs 0.000 claims 1
- 229940121375 antifungal agent Drugs 0.000 claims 1
- 239000003429 antifungal agent Substances 0.000 claims 1
- 229940030225 antihemorrhagics Drugs 0.000 claims 1
- 239000000739 antihistaminic agent Substances 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 239000003096 antiparasitic agent Substances 0.000 claims 1
- 229940125687 antiparasitic agent Drugs 0.000 claims 1
- 239000003904 antiprotozoal agent Substances 0.000 claims 1
- 239000003435 antirheumatic agent Substances 0.000 claims 1
- 239000003699 antiulcer agent Substances 0.000 claims 1
- 229960000074 biopharmaceutical Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000003633 blood substitute Substances 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 239000000168 bronchodilator agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 239000003224 coccidiostatic agent Substances 0.000 claims 1
- 239000003433 contraceptive agent Substances 0.000 claims 1
- 230000002254 contraceptive effect Effects 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002934 diuretic Substances 0.000 claims 1
- 230000001882 diuretic effect Effects 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 230000003419 expectorant effect Effects 0.000 claims 1
- 229940066493 expectorants Drugs 0.000 claims 1
- 239000000122 growth hormone Substances 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 239000002874 hemostatic agent Substances 0.000 claims 1
- 230000002439 hemostatic effect Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 238000002657 hormone replacement therapy Methods 0.000 claims 1
- 229960001438 immunostimulant agent Drugs 0.000 claims 1
- 239000003022 immunostimulating agent Substances 0.000 claims 1
- 230000003308 immunostimulating effect Effects 0.000 claims 1
- 208000000509 infertility Diseases 0.000 claims 1
- 230000036512 infertility Effects 0.000 claims 1
- 231100000535 infertility Toxicity 0.000 claims 1
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 1
- 239000011707 mineral Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 229940035363 muscle relaxants Drugs 0.000 claims 1
- 239000003158 myorelaxant agent Substances 0.000 claims 1
- 229930014626 natural product Natural products 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940023490 ophthalmic product Drugs 0.000 claims 1
- 229940124583 pain medication Drugs 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 229940125723 sedative agent Drugs 0.000 claims 1
- 239000000932 sedative agent Substances 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 239000003204 tranquilizing agent Substances 0.000 claims 1
- 230000002936 tranquilizing effect Effects 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPR761401 | 2001-09-11 | ||
| PCT/AU2002/000868 WO2003022242A1 (en) | 2001-09-11 | 2002-07-01 | Preparation of sustained release pharmaceutical composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005505557A JP2005505557A (ja) | 2005-02-24 |
| JP2005505557A5 true JP2005505557A5 (OSRAM) | 2006-01-12 |
Family
ID=3831520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003526372A Withdrawn JP2005505557A (ja) | 2001-09-11 | 2002-07-01 | 持続放出医薬組成物の調製 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20040234572A1 (OSRAM) |
| EP (1) | EP1424994A4 (OSRAM) |
| JP (1) | JP2005505557A (OSRAM) |
| CN (1) | CN1541090A (OSRAM) |
| BR (1) | BR0212052A (OSRAM) |
| CA (1) | CA2452194A1 (OSRAM) |
| CO (1) | CO5560533A2 (OSRAM) |
| NZ (1) | NZ530550A (OSRAM) |
| WO (1) | WO2003022242A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW586934B (en) * | 1997-05-19 | 2004-05-11 | Sumitomo Pharma | Immunopotentiating composition |
| US20050129728A1 (en) * | 2001-09-11 | 2005-06-16 | Martinod Serge R. | Sustained release pharmaceutical composition |
| US20050232972A1 (en) | 2004-04-15 | 2005-10-20 | Steven Odrich | Drug delivery via punctal plug |
| CA2568641A1 (en) * | 2004-05-31 | 2005-12-15 | Smart Drug Systems Inc | Sustained release composition |
| JP2008502605A (ja) | 2004-06-16 | 2008-01-31 | スマート ドラッグ システムズ インコーポレイティド | 徐放性ワクチン組成物 |
| CA2572592C (en) | 2004-07-02 | 2015-09-08 | Eliot Lazar | Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device |
| US8541028B2 (en) | 2004-08-04 | 2013-09-24 | Evonik Corporation | Methods for manufacturing delivery devices and devices thereof |
| US8864730B2 (en) | 2005-04-12 | 2014-10-21 | Rochester Medical Corporation | Silicone rubber male external catheter with absorbent and adhesive |
| US9695953B2 (en) * | 2006-02-14 | 2017-07-04 | B. Braun Medical Inc. | Needleless access port valves |
| SG170806A1 (en) | 2006-03-31 | 2011-05-30 | Qlt Plug Delivery Inc | Nasolacrimal drainage system implants for drug therapy |
| WO2008064173A2 (en) * | 2006-11-17 | 2008-05-29 | B. Braun Medical Inc. | Antimicrobial silicone rubber injection port valves |
| ES2732555T3 (es) | 2007-09-07 | 2019-11-25 | Mati Therapeutics Inc | Implantes lagrimales y métodos relacionados |
| MX2010002619A (es) | 2007-09-07 | 2010-06-01 | Qlt Plug Delivery Inc | Deteccion de implante lagrimal. |
| ES2533359T3 (es) * | 2007-09-07 | 2015-04-09 | Mati Therapeutics Inc. | Núcleos de fármaco para liberación sostenida de agentes terapéuticos |
| ES2718612T3 (es) | 2007-12-20 | 2019-07-03 | Evonik Corp | Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual |
| CN104623741A (zh) | 2008-04-30 | 2015-05-20 | 马缇医疗股份有限公司 | 复合泪管植入物及相关方法 |
| EP2276492A2 (en) | 2008-05-09 | 2011-01-26 | QLT Plug Delivery, Inc. | Sustained release delivery of active agents to treat glaucoma and ocular hypertension |
| CA2752645C (en) | 2009-02-23 | 2017-10-03 | Qlt Inc. | Lacrimal implants and related methods |
| US9707375B2 (en) | 2011-03-14 | 2017-07-18 | Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. | Catheter grip and method |
| US9974685B2 (en) | 2011-08-29 | 2018-05-22 | Mati Therapeutics | Drug delivery system and methods of treating open angle glaucoma and ocular hypertension |
| DK3290024T3 (da) | 2011-08-29 | 2019-06-03 | Mati Therapeutics Inc | Vedvarende indgivelse af aktive midler til behandling af glaukom og okulær hypertension |
| US9872969B2 (en) | 2012-11-20 | 2018-01-23 | Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. | Catheter in bag without additional packaging |
| US10092728B2 (en) | 2012-11-20 | 2018-10-09 | Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. | Sheath for securing urinary catheter |
| JP6340673B2 (ja) | 2013-05-02 | 2018-06-13 | レティナ ファウンデーション オブ ザ サウスウエストＲｅｔｉｎａ Ｆｏｕｎｄａｔｉｏｎ Ｏｆ Ｔｈｅ Ｓｏｕｔｈｗｅｓｔ | 二層型眼用インプラント |
| CL2014000989A1 (es) * | 2014-04-17 | 2014-10-17 | Univ Santiago Chile | Dispositivo subdermal de liberacion prolongada y lenta para prevencion, tratamiento y monitoreo de parasitos, que comprende al menos una lactona macrociclica tal como ivermectina y/o dormectina, opcionalmente nanoparticulas o microparticulas de zeolita, una matriz polimerica y medios de monitoreo, dentro de un circuito integrado. |
| TW201618783A (zh) | 2014-08-07 | 2016-06-01 | 艾森塔製藥公司 | 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法 |
| EP3169378B1 (en) | 2014-08-26 | 2021-09-29 | C.R. Bard Inc. | Urinary catheter |
| EP3675779B1 (en) | 2017-09-19 | 2025-09-10 | C. R. Bard, Inc. | Urinary catheter bridging device, systems and methods thereof |
| ES2942731T3 (es) * | 2019-02-22 | 2023-06-06 | Elkem Silicones Usa Corp | Composición de silicona de administración de fármacos para mejorar la elución de ingredientes activos |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3279996A (en) * | 1962-08-28 | 1966-10-18 | Jr David M Long | Polysiloxane carrier for controlled release of drugs and other agents |
| US4053580A (en) * | 1975-01-01 | 1977-10-11 | G. D. Searle & Co. | Microsealed pharmaceutical delivery device |
| IE56979B1 (en) * | 1984-02-14 | 1992-02-26 | Drug Systems Res & Dev | Subcutaneous implant |
| US5028430A (en) * | 1987-05-08 | 1991-07-02 | Syntex (U.S.A.) Inc. | Delivery systems for the controlled administration of LHRH analogs |
| US4861596A (en) * | 1988-03-21 | 1989-08-29 | Pfizer Inc. | Rolled matrix device having enhanced ability to unroll and method for its production |
| FR2653338B1 (fr) * | 1989-10-23 | 1994-06-10 | Dow Corning Sa | Formulation pour des pansements a liberation prolongee de medicament et son utilisation. |
| JPH05238929A (ja) * | 1992-02-27 | 1993-09-17 | Sumitomo Pharmaceut Co Ltd | 代謝性骨疾患治療用長期持続性製剤 |
| WO1996025852A1 (en) * | 1995-02-24 | 1996-08-29 | Novartis Ag | Composition for controlling parasites |
| US6395029B1 (en) * | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
| US6998137B2 (en) * | 2000-04-07 | 2006-02-14 | Macromed, Inc. | Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix |
| AUPR602401A0 (en) * | 2001-06-29 | 2001-07-26 | Smart Drug Systems Inc | Sustained release delivery system |
-
2002
- 2002-07-01 WO PCT/AU2002/000868 patent/WO2003022242A1/en not_active Ceased
- 2002-07-01 CA CA002452194A patent/CA2452194A1/en not_active Abandoned
- 2002-07-01 BR BR0212052-6A patent/BR0212052A/pt not_active IP Right Cessation
- 2002-07-01 NZ NZ530550A patent/NZ530550A/en not_active IP Right Cessation
- 2002-07-01 EP EP02740130A patent/EP1424994A4/en not_active Withdrawn
- 2002-07-01 US US10/487,714 patent/US20040234572A1/en not_active Abandoned
- 2002-07-01 CN CNA028159136A patent/CN1541090A/zh active Pending
- 2002-07-01 JP JP2003526372A patent/JP2005505557A/ja not_active Withdrawn
-
2004
- 2004-02-25 CO CO04016759A patent/CO5560533A2/es not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005505557A5 (OSRAM) | ||
| ES2205177T5 (es) | Composicion en polvo para administracion nasal. | |
| RU2404750C2 (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda рецептора, способ введения такого nmda антагониста субъекту | |
| US4940587A (en) | Oral pharmaceutical composition through mucosa | |
| KR100449538B1 (ko) | 개별유니트의경구투여 | |
| JP2005510535A5 (OSRAM) | ||
| CN114340640A (zh) | 用于治疗、改善或预防冠状病毒感染的制造产品和方法 | |
| JP2005515966A5 (OSRAM) | ||
| JP2005515996A5 (OSRAM) | ||
| TW200412934A (en) | Pharmaceutical formulations of modafinil | |
| JP2004530721A5 (OSRAM) | ||
| CN101325944A (zh) | 用于鼻部给药的组合物 | |
| Wertheimer et al. | Drug delivery systems improve pharmaceutical profile and facilitate medication adherence | |
| JP2004529207A5 (OSRAM) | ||
| JP5542309B2 (ja) | 経口医薬組成物 | |
| CN101309675A (zh) | 口服剂量组合的药品包装 | |
| JP2003176227A (ja) | 製薬組成物、喫煙を控えている患者の喫煙禁断症状を軽減する方法及び患者の喫煙禁断症状を軽減するキット | |
| WO1995006460A1 (en) | Dispenser containing hydrophobic agent | |
| EA002197B1 (ru) | Препараты левозимендана, предназначенные для введения через слизистую оболочку | |
| ES2286716T3 (es) | Composicion farmaceutica de liberacion controlada y proceso para preparar la misma. | |
| RU2002111000A (ru) | Способ терапевтического лечения внематочной пролиферации эндометриальной ткани, хронической боли в области таза и непроходимости фаллопиевых труб, фармацевтическая композиция и анатагонист LHRH-лекарственное средство для указанного лечения (варианты) | |
| NZ747702A (en) | Melatonin mini-tablets and method of manufacturing the same | |
| ES2356371T3 (es) | Medicamentos terapéuticos para inducir tolerancia. | |
| JP2006001920A (ja) | 医薬製剤 | |
| JP2004523536A5 (OSRAM) |